Our results showed that mAbs, ADCs, PD-1/PD-L1 inhibitors, and mTOR inhibitors were associated with ILD, although not found in PARP inhibitors and CDK4/6 inhibitors, there remains a risk of occurrence that should not be ignored. This evidence concerns the gene CDK4 and interstitial lung disease.